ESR1 and breast carcinoma: Our previous studies revealed that CK2α mRNA expression was a predictive marker for shorter relapse-free survival among patients with ER(+) breast cancer, as well as for those with histological grade 1 or 2 tumors, and among those treated with hormone-based therapy [4].